Loading
Ovarian Function and Disorders · Journal article
Medical Times · September 10, 2026
Encouraging direction, but not yet definitive.
This randomized double-blind trial of 96 obese hyperinsulinemic women with PCOS/PMOS found that combined inositol (MI+DCI) improved insulin resistance and glucose metabolism more than MI alone, and further improvements followed ALA addition, with menstrual regularity restored most often in the triple-combination group. The results are consistent with a dose-response effect but rely on surrogate metabolic and hormonal endpoints without hard clinical outcomes, and lack key methodological details.
Randomized, double-blind, parallel-group controlled trial. Women aged 20–38 years with obesity (BMI ≥30 kg/m²), Rotterdam criteria-defined PCOS/PMOS, hyperinsulinemia, and insulin resistance, all with family history of diabetes.. Intervention: Myo-inositol (MI), or MI + D-chiro-inositol (DCI) at 40:1 ratio, or MI + DCI + alpha-lipoic acid (ALA). Compared with: Control group (unspecified). n = 96.
MI+DCI combination produced greater improvements in insulin resistance and glucose metabolism than MI alone after 24 weeks Addition of ALA to MI+DCI resulted in further improvement across key metabolic outcomes Menstrual regularity was restored most frequently with MI+DCI+ALA, followed by MI+DCI and MI alone
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing PCOS with metabolic dysfunction may find the dose-response pattern suggestive, but should note that menstrual regularity and hormonal improvements do not yet establish fertility or long-term health benefits. Confirmation in a larger, longer trial with reproductive and cardiovascular outcomes is needed before practice change.
A randomized double-blind trial with 96 participants showing dose-response improvements in insulin resistance, hormonal markers, and menstrual regularity over 24 weeks, but limited by single-center design, surrogate endpoints, and lack of hard clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing PCOS with metabolic dysfunction may find the dose-response pattern suggestive, but should note that menstrual regularity and hormonal improvements do not yet establish fertility or long-term health benefits. Confirmation in a larger, longer trial with reproductive and cardiovascular outcomes is needed before practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Polyendocrine Metabolic Ovarian Syndrome (PCOS/PMOS) represents a complex metabolic-endocrine disorder in obese, hyperinsulinemic, and insulin-resistant women with a family history of diabetes. Myo-inositol (MI) and D-chiro-inositol (DCI) act as insulin-sensitizing agents, while alpha-lipoic acid (ALA) may provide additional metabolic benefits. However, comparative evidence regarding their combined effects in this high-risk population remains limited. Objective of the article is to compare the metabolic, hormonal, and clinical effects of MI, MI+DCI, and MI+DCI+ALA in obese, hyperinsulinemic women with PCOS/PMOS and a family history of diabetes. Methods: In this randomized, double-blind, parallel-group clinical trial, 96 women aged 20–38 years with obesity (BMI ≥30 kg/m²), Rotterdam criteria-defined PCOS/PMOS, hyperinsulinemia, and insulin resistance were randomized to control, MI, MI+DCI (40:1), or MI+DCI+ALA groups. Participants were evaluated at baseline and after 12 and 24 weeks. Metabolic, hormonal, and clinical parameters, including insulin sensitivity, glucose metabolism, androgen status, lipid profile, anthropometric measures, and menstrual regularity, were assessed. Results: After 24 weeks, all three treatment groups demonstrated improvements in metabolic and hormonal parameters compared with controls. The MI+DCI combination produced greater improvements in insulin resistance and glucose metabolism than MI alone, while the addition of ALA resulted in further improvement. Androgen levels decreased, and SHBG increased, accompanied by improved gonadotropin balance. Menstrual regularity was restored most frequently with MI+DCI+ALA, followed by MI+DCI and MI alone. Anthropometric and lipid parameters also improved, with the most pronounced overall metabolic effects observed with the triple combination. Improvements in hepatic insulin extraction and liver-related parameters were particularly evident following ALA addition. Conclusions: In obese women with PCOS/PMOS, hyperinsulinemia, insulin resistance and a family history of diabetes, MI+DCI supplementation was associated with greater metabolic, hormonal and clinical benefits than MI alone, while the addition of ALA provided further improvement across key metabolic outcomes. These findings support the potential role of combined inositol and ALA therapy in managing PCOS/PMOS phenotypes characterized by increased metabolic risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.